MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,206K
Net Income
-$6,671K
Net Profit Margin
-553.15%
EPS
-$0.26
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-03-31
2024-12-31
2024-09-30
2024-06-30
Sales and marketing
1,206
1,100*
1,043
853
Research and development
2,924
1,934*
2,817
2,453
Impairment losses
-
10,475*
-
-
General and administrative
3,115
2,746*
2,565
2,407
Impairment loss on held for sale assets
-
-42*
-
-
Change in fair value of contingent consideration
879
18,113*
7,140
-1,031
Total operating expenses
8,124
34,410*
13,565
4,682
Net revenue
2,138
1,553*
115
104
Cost of revenues
806
941*
43
32
Cost of revenues amortization of acquired intangibles
7
22*
22
22
Gross profit
1,325
590*
50
50
Loss from operations
-6,799
-33,820*
-13,515
-4,632
Other income, net
157
218*
53
110
Interest expense
-29
-25*
-31
-8
Total other income, net
128
192*
22
102
Loss before income taxes
-6,671
-33,628
-13,493
-4,530
Net loss
-6,671
-33,628
-13,493
-4,530
Basic EPS
-0.26
-2.663
-0.98
-0.36
Diluted EPS
-0.26
-2.663
-0.98
-0.36
Basic Average Shares
25,694,000
12,629,000
13,714,000
12,870,000
Diluted Average Shares
25,694,000
12,629,000
13,714,000
12,870,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$6,671K
Other income, net
$157K
Loss before income
taxes
-$6,671K
Total other income,
net
$128K
Net revenue
$2,138K
Interest expense
-$29K
Loss from operations
-$6,799K
Gross profit
$1,325K
Cost of revenues
$806K
Cost of revenues
amortization of acquired...
$7K
Total operating
expenses
$8,124K
General and
administrative
$3,115K
Research and development
$2,924K
Sales and marketing
$1,206K
Change in fair value of
contingent consideration
$879K
Buy us a coffee
Oncocyte Corp (OCX)
Oncocyte Corp (OCX)